Genetic Studies in Treatment-Resistant Schizophrenia

2010 ◽  
pp. 52-62 ◽  
Author(s):  
Vincenzo De Luca ◽  
Renan P Souza ◽  
Fabio Panariello ◽  
Herbert Y Meltzer
Keyword(s):  
Treatment Resistant ◽  
Genetic Studies

scholarly journals Genetic and Adverse Health Outcome Associations with Treatment Resistant Hypertension in GenHAT

2013 ◽  
Vol 2013 ◽  
pp. 1-10 ◽  
Author(s):  
Amy I. Lynch ◽  
Marguerite R. Irvin ◽  
Barry R. Davis ◽  
Charles E. Ford ◽  
John H. Eckfeldt ◽  
...  
Keyword(s):  
Resistant Hypertension ◽  
Genetic Variants ◽  
Antihypertensive Medication ◽  
Genetic Basis ◽  
Uncontrolled Hypertension ◽  
Treatment Resistant ◽  
Adverse Health Outcome ◽  
Genetic Studies ◽  
Similar Association ◽  
Agt Gene

Treatment resistant hypertension (TRH) is defined as uncontrolled hypertension (HTN) despite the use of ≥3 antihypertensive medication classes or controlled HTN while treated with ≥4 antihypertensive medication classes. Risk factors for TRH include increasing age, diminished kidney function, higher body mass index, diabetes, and African American (AA) race. Importantly, previous studies suggest a genetic role in TRH, although the genetics of TRH are largely understudied. With 2203 treatment resistant cases and 2354 treatment responsive controls (36% AA) from the Genetics of Hypertension Associated Treatment Study (GenHAT), we assessed the association of 78 candidate gene polymorphisms with TRH status using logistic regression. After stratifying by race and adjusting for potential confounders, there were 2 genetic variants in the AGT gene (rs699, rs5051) statistically significantly associated with TRH among white participants. The Met allele of rs699 and the G allele of rs5051 were positively associated with TRH:OR=1.27 (1.12–1.44),P=0.0001, andOR=1.36 (1.20–1.53),P<0.0001, respectively. There was no similar association among AA participants (race interactionP=0.0004for rs699 andP=0.0001for rs5051). This research contributes to our understanding of the genetic basis of TRH, and further genetic studies of TRH may help reach the goal of better clinical outcomes for hypertensive patients.

Moving beyond the “LDL hypothesis”

VASA ◽  
2015 ◽  
Vol 44 (5) ◽  
pp. 333-340 ◽  
Author(s):  
Christian Werner ◽  
Ulrich Laufs
Keyword(s):  
Ldl Cholesterol ◽  
Causal Relation ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Clinical Trial Data ◽  
Randomised Clinical Trial ◽  
Trial Data ◽  
Low Density Lipoprotein Cholesterol ◽  
Genetic Studies ◽  
Statin Drug

Abstract. Summary: The term “LDL hypothesis” is frequently used to describe the association of low-density lipoprotein cholesterol (LDL-cholesterol, LDL-C) and cardiovascular (CV) events. Recent data from genetic studies prove a causal relation between serum LDL-C and CV events. These data are in agreement with mechanistic molecular studies and epidemiology. New randomised clinical trial data show that LDL-C lowering with statins and a non-statin drug, ezetimibe, reduces CV events. We therefore believe that the “LDL-hypothesis” has been proven; the term appears to be outdated and should be replaced by “LDL causality”.

Management of Treatment-Resistant Epilepsy Volume 1. Evidence Report and Appendices: Evidence Report/Technology Assessment, Number 77

2003 ◽  
Author(s):  
Richard Chapell ◽  
James Reston ◽  
David Snyder ◽  
Jonathan Treadwell ◽  
Stephen Tregear ◽  
...  
Keyword(s):  
Technology Assessment ◽  
Treatment Resistant
Sign in / Sign up

Export Citation Format

Share Document